+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Fifteen-year results with the Hancock II valve: a multicenter experience



Fifteen-year results with the Hancock II valve: a multicenter experience



Journal of Thoracic and Cardiovascular Surgery 132(3): 602



The purpose of this multi-institutional study was to review the 15-year outcome of patients who received isolated aortic or mitral valve replacement with the Hancock II bioprosthesis. From 1983 through 2002, 1274 patients underwent 1293 isolated valve replacements, 809 aortic valve replacements and 484 mitral valve replacements, at hospitals in the Venetian area (Padova, Treviso, and Venice). Mean age was 68 +/- 8 years in patients undergoing aortic valve replacement and 66 +/- 9 years in patients undergoing mitral valve replacement; 52% of patients undergoing aortic valve replacement and 63% of patients undergoing mitral valve replacement were in New York Heart Association class III or greater. Coronary artery disease was present in 32% of patients who had undergone aortic valve replacement and 18% of patients who had undergone mitral valve replacement. Follow-up included 8520 patient-years, with a median of 12 years, and was 97% complete. Overall 15-year survival was 39.7% +/- 2.4%, similar in both the aortic and mitral positions. Multivariable analysis of late survival showed the incremental risk of male sex, higher New York Heart Association class, coronary artery disease, and mitral position. Freedom from embolism was higher in the aortic position (81% +/- 2.9% in aortic vs 72% +/- 4.7% in mitral valve replacements). Freedom from endocarditis was similar in the aortic and mitral position (95% +/- 1.2% vs 94% +/- 1.7%). Freedom from reoperation (82% +/- 3.7% vs 71% +/- 5.0%) and from valve-related morbidity-mortality (52% +/- 3.6% vs 36% +/- 4.4%) was higher in patients who had undergone AVR. Actual freedom from structural valve deterioration for patients 60 years and older who had undergone aortic valve replacement was 96.5% +/- 1.3% versus 88% +/- 3.2% for patients who had undergone mitral valve replacement and 70% +/- 7.5% versus 77.5% +/- 5.3%, respectively, in younger patients. Multivariable Weibull analysis showed structural valve deterioration related to younger age and preoperative valve incompetence and inversely related to coronary artery disease. Optimal 15-year durability can be expected in male patients 60 years and older who have undergone aortic valve replacement and in male patients 65 years and older who have undergone mitral valve replacement, extending safely the age limits for the use of this valve.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 049081013

Download citation: RISBibTeXText

PMID: 16935116

DOI: 10.1016/j.jtcvs.2006.05.031


Related references

Fifteen-year experience with 1678 Hancock porcine bioprosthetic heart valve replacements. Annals of Surgery 210(4): 435, 1989

Atrioventricular valve replacement with the Hancock porcine xenograft: a five year clinical experience. Surgery 78(6): 768-775, 1975

The pathology of Hancock standard porcine valve prosthesis: a 20-year span of experience. Journal of Cardiac Surgery 5(4): 328-335, 1990

Long term results after 15 years of experience with the bioprosthesis hancock valve. Journal of Cardiovascular Surgery 32(4 Suppl.): 86, 1991

Atrio-ventricular valve replacement with the Hancock Porcine xenograft: a five year clinical experience. Journal of Cardiovascular Surgery 17(1): 98, 1976

Performance of the Hancock porcine bioprosthesis following aortic valve replacement: considerations based on a 15-year experience. Annals of Thoracic Surgery 46(2): 216-222, 1988

Fifteen-year experience with 24 pregnancies associated with prosthetic valve replacements. Journal of Cardiology 20(4): 929-935, 1990

Long-term durability of the Hancock porcine bioprosthesis following combined mitral and aortic valve replacement: an 11-year experience. Annals of Thoracic Surgery 44(2): 139-144, 1987

Intermediate term results of isolated mitral valve replacement with glutaraldehyde-preserved porcine xenograft valve: clinical and hemodynamic comparison between Hancock valve and Angell-Shiley valve. Tohoku Journal of Experimental Medicine 150(1): 37-50, 1986

Fifteen-year experience with the Bicarbon heart valve prosthesis in a single center. Journal of Cardiothoracic Surgery 10: 89, 2015

European multicenter study with the Soprano valve for aortic valve replacement: one-year clinical experience and hemodynamic data. Journal of Heart Valve Disease 20(6): 695-703, 2011

Fifteen-year experience with minimally invasive approach for reoperations involving the mitral valve. Journal of Thoracic and Cardiovascular Surgery 143(5): 1062-1068, 2012

Early and Midterm Clinical and Hemodynamic Outcomes of Transcatheter Valve-in-Valve Implantation: Results From a Multicenter Experience. Annals of Thoracic Surgery 102(6): 1966-1973, 2016

Fifteen-year experience with the medtronic-hall valve prosthesis. A follow-up study of 1104 consecutive patients. Circulation 94(9 Suppl.): Ii105-8, 1996

Failure of Hancock xenograft valve: importance of valve position (4- to 9-year follow-up). Annals of Thoracic Surgery 36(3): 246-252, 1983